Company: PETVW
Filing Date: 2025-07-10
Form Type: 10-K
Source: 0001641172-25-018617
Chunk: 814

Company: PetVivo Holdings, Inc.
Filing Date: 2025-07-10
Form: 10-K
Item: Item 7
Chunk 814
---
The
following discussion of our financial condition and results of operations should be read in conjunction with our financial statements
and related notes that appear elsewhere in this prospectus. In addition to historical consolidated financial information, the following
discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. Our actual results could differ materially
from those discussed in the forward-looking statements. Factors that could cause or contribute to those differences include those discussed
below and elsewhere in this prospectus, particularly in “RISK FACTORS.” We caution the reader not to place undue reliance
on these forward-looking statements, which reflect management’s analysis only as of the date of this prospectus.

We
are a smaller reporting company and have not generated any material revenues to date and have incurred substantial losses in connection
with our limited operations. We need substantial capital to pursue our current plans to bring our first products to market. The first
of such products is a proprietary gel-like protein-based biomedical material for injection into the afflicted body parts of animals suffering
from osteoarthritis or other impairments to be marketed under the trade name Spryng®, formerly known as Spryng®. It will provide
veterinarians an innovative treatment for dogs and horses suffering from osteoarthritis.

The
independent auditor’s report accompanying our March 31, 2025, financial statements contain an explanatory paragraph expressing
substantial doubt about our ability to continue as a going concern. The financial statements have been prepared “assuming that
we will continue as a going concern,” which contemplates that we will realize our assets and satisfy our liabilities and commitments
in the ordinary course of business. We have suffered recurring losses from operations, and our working capital is insufficient to fund
our operations for the next 12 months. These factors raise substantial doubt about our ability to continue as a going concern.

RESULTS
OF OPERATION

    For Fiscal Year Ended March 31, 

    2025  
    2024 
  
    Revenues 
    $1,132,533  
    $968,706 
  
    Total Cost of Sales 
     137,677  
     101,823 
  
    Total Operating Expenses 
     9,050,575  
     11,488,223 
  
    Total Other Income (Expense) 
     (343,446) 
     (335,955)
  
    Net Loss 
     (8,399,166) 
     (10,955